-
. However, progress is constrained by the scarcity of high-quality, well-characterized in vitro T-cell immunogenicity data. In this project, we will leverage expertise and technology in peptide T-cell
-
and their mechanisms due to advances in biomedical sciences; many promising therapeutic approaches are still clinically unavailable. This is simply because there is no efficient means of delivering
Enter an email to receive alerts for systems-science-"https:"-"https:"-"IFM" positions